Biomarkers in Ulcerative Colitis
Publication Date: February 20, 2023
Key Points
Key Points
- There is an important need for understanding how noninvasive biomarkers may serve as accurate and reliable surrogates for endoscopic assessment of inflammation.
- Commonly available biomarkers are well-established as surrogate tests for endoscopic assessment of disease and in longitudinal monitoring of patients with an established diagnosis of ulcerative colitis (UC).
- This guideline focuses on the following biomarkers: serum C-reactive protein (CRP), fecal calprotectin, and fecal lactoferrin.
Diagnosis
...agnosi...
...ry of Recommendations...
...With Ulcerative Colitis in Symptom...
...nts with UC in symptomatic remission,...
...l calprotectin...
...mal fecal lactoferrin (C, L)620...
...CRP (C, VL)Implementation consideration:...
...ents with UC in symptomatic remission b...
...h Symptomatically Active Ulcerative...
...h symptomatically active UC, the AGA su...
...alprotectin >150 μg/g (C, L)620...
...cal lactoferrin (C, VL)620...
...evated CRP (C, M)6...
...tients with UC with mild symptoms,...
...with UC with mild symptoms, with n...
...Strategies for Ulcerative Colitis...
...with UC, the AGA makes no recommenda...
...y Considerations When Using Biomarkers for M...
Treatment
Treatme...
...f Diagnostic Test Results on Patient-Important...